STERO, founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy.
STERO’s extremely wide coverage patent (CBD from any source, in any combination, any dosage, in any delivery system, all for more than 130 diseases by name) was Issued in the US on August 2018 and is pending in main countries around the world.
Stero currently has 3 ongoing clinical trials, 2 phase 2a clinical trials in Crohn's disease, and in Chronic Urticaria (Hives), 1 phase 1/2 clinical trial treating severe covid-19 patients, all covered by Stero’s IP & pursuing the FDA drug route, with more in the pipeline.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 14 Baruch Hirsh St, Bnei Brak,israel 5120206,israel
- Industry
- Biotechnology
- Website
- http://www.sterobiotechs.com
- HQ
- Bnei Brak, Israel
Stero Biotechs Questions
Stero Biotechs's website is http://www.sterobiotechs.com
Stero Biotechs's LinkedIn profile is https://cz.linkedin.com/company/stero-biotechs
Stero Biotechs has
2 employees.
View email and phone details for 2
employees at Stero Biotechs.
Stero Biotechs's industry is
Biotechnology
Stero Biotechs's top competitors are
Rhinocare,
Lykos Therapeutics,
Scentech Medical, Ltd.,
Cannalean Biotechs,
Biokine Therapeutics Ltd.,
Talent Fund,
Scopus Research,
Cannamore Biotechs,
Biokine.com.mx,
Aporx.
Stero Biotechs's categories are Biotechnology
Stero Biotechs's founding year is 2017
